Originally published as JCO Early Release 10.1200/JCO.2006.10.2434 on June 18 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, E. A. Articles by Duvic, M. Search for Related Content PubMed PubMed Citation Articles by Olsen, E. A. Articles by Duvic, M. Related Articles Related Correspondence

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker, Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduino, Madeleine Duvic

From Duke University, Durham, NC; Stanford University, Stanford, CA; Northwestern University, Chicago, IL; University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO; Tufts-New England Medical Center, Boston, MA; Emory University, Atlanta, GA; Merck Research Laboratories, Upper Gwynedd, PA; and the M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Elise A. Olsen, MD, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC 27710; e-mail: olsen001{at}mc.duke.edu

Purpose: To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.

Patients and Methods: Patients with stage IB-IVA MF/SS were treated with 400 mg of oral vorinostat daily until disease progression or intolerable toxicity in this open-label phase IIb trial (NCT00091559). Patients must have received at least two prior systemic therapies at least one of which included bexarotene unless intolerable. The primary end point was the objective response rate (ORR) measured by the modified severity weighted assessment tool and secondary end points were time to response (TTR), time to progression (TTP), duration of response (DOR), and pruritus relief ( 3-point improvement on a 10-point visual analog scale). Safety and tolerability were also evaluated.

Results: Seventy-four patients were enrolled, including 61 with at least stage IIB disease. The ORR was 29.7% overall; 29.5% in stage IIB or higher patients. Median TTR in stage IIB or higher patients was 56 days. Median DOR was not reached but estimated to be 185 days (34+ to 441+). Median TTP was 4.9 months overall, and 9.8 months for stage IIB or higher responders. Overall, 32% of patients had pruritus relief. The most common drug-related adverse experiences (AE) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%); most were grade 2 or lower but those grade 3 or higher included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%). Eleven patients required dose modification and nine discontinued due to AE.

Conclusion: Oral vorinostat was effective in treatment refractory MF/SS with an acceptable safety profile.

published online ahead of print at www.jco.org on July 18, 2007.

Supported by research funding from Merck Research Laboratories.

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology in Atlanta, GA, June 3-6, 2006; and at the 48th Annual Meeting of the American Society of Hematology in Orlando, FL, December 9-12, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat)
  Lei Zhang, David Lebwohl, Eric Masson, Glen Laird, Michael R. Cooper, and H. Miles Prince
  JCO 2008 26: 332-333 [Full Text]

This article has been cited by other articles:

				V. R. Fantin, A. Loboda, C. P. Paweletz, R. C. Hendrickson, J. W. Pierce, J. A. Roth, L. Li, F. Gooden, S. Korenchuk, X. S. Hou, et al. Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma Cancer Res., May 15, 2008; 68(10): 3785 - 3794. [Abstract] [Full Text] [PDF]

				M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 964 - 969. [Abstract] [Full Text] [PDF]

				L. L. Siu, R. Pili, I. Duran, W. A. Messersmith, E. X. Chen, R. Sullivan, M. MacLean, S. King, S. Brown, G. K. Reid, et al. Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors J. Clin. Oncol., April 20, 2008; 26(12): 1940 - 1947. [Abstract] [Full Text] [PDF]

				G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W. G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood, February 1, 2008; 111(3): 1060 - 1066. [Abstract] [Full Text] [PDF]

				L. Zhang, D. Lebwohl, E. Masson, G. Laird, M. R. Cooper, and H. M. Prince Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat) J. Clin. Oncol., January 10, 2008; 26(2): 332 - 333. [Full Text] [PDF]

				E. L. Strevel and L. L. Siu In Reply J. Clin. Oncol., January 10, 2008; 26(2): 333 - 334. [Full Text] [PDF]

				M. T. Epping, L. Wang, J. A. Plumb, M. Lieb, H. Gronemeyer, R. Brown, and R. Bernards A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors PNAS, November 6, 2007; 104(45): 17777 - 17782. [Abstract] [Full Text] [PDF]

				B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma Oncologist, October 1, 2007; 12(10): 1247 - 1252. [Abstract] [Full Text] [PDF]